Great debate here on Zenith forum ! I believe Don and company are planning same arrangement as was previously done with Resverlogics and (spinco ) Resverlogic therapeutics name changed to Zenith . Don has spoke of rewarding longterm shareholders with royalties from successful drugs the company developes and sheltering those royalty streams. I believe this once again ,is his strategy for returning back to loyal committed stakeholders dividends ... And means of funding trials and development with IPO assuring ability to foster strategic licensing deals among counties / pharmas My two cents Stock